Glaxo aims to lure patients from Novartis' Xolair with Nucala switching study

5th March 2018 Uncategorised 0

GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis. Monday at the joint congress of the American Academy of Allergy, Asthma & Immunology and World Allergy Organization, the pharma giant rolled out data showing that switching uncontrolled Xolair patients to GSK’s Nucala improved asthma control.

More: Glaxo aims to lure patients from Novartis' Xolair with Nucala switching study
Source: fierce